☰

Rainer Brachmann - Publications

Affiliations: 
Washington University, Saint Louis, St. Louis, MO 
Area:
Molecular Biology, Oncology, Cell Biology
Tree Info Grants Similar researchers PubMed Report error

14 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Dotan E, Cardin DB, Lenz HJ, Messersmith WA, O'Neil BH, Cohen SJ, Denlinger CS, Shahda S, Astsaturov I, Kapoun AM, Brachmann R, Uttamsingh S, Stagg R, Weekes CD. Phase 1b study of Wnt inhibitor ipafricept (IPA) with gemcitabine and nab-paclitaxel in patients with previously untreated stage IV pancreatic cancer (mPDAC). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32694153 DOI: 10.1158/1078-0432.CCR-20-0489  0.371
2019 Moore KN, Gunderson CC, Sabbatini P, McMeekin DS, Mantia-Smaldone G, Burger RA, Morgan MA, Kapoun AM, Brachmann RK, Stagg R, Farooki A, O'Cearbhaill RE. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecologic Oncology. PMID 31174889 DOI: 10.1016/j.ygyno.2019.04.001  0.345
2018 Xu B, Yin Y, Song Y, Li W, Huang X, Brachmann R, Tang T, Yang H, Ge R, Mu S, Zhang K, Li M, Dong M. Abstract CT050: A phase I dose escalation study of BGB-290 in Chinese subjects with advanced ovarian, fallopian, and primary peritoneal, or advanced triple-negative breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct050  0.318
2011 Kobayashi T, Ishida J, Musashi M, Ota S, Yoshida T, Shimizu Y, Chuma M, Kawakami H, Asaka M, Tanaka J, Imamura M, Kobayashi M, Itoh H, Edamatsu H, Sutherland LC, ... Brachmann RK, et al. p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5. International Journal of Cancer. 128: 304-18. PMID 20309933 DOI: 10.1002/ijc.25345  0.601
2007 Wang T, Zeng J, Lowe CB, Sellers RG, Salama SR, Yang M, Burgess SM, Brachmann RK, Haussler D. Species-specific endogenous retroviruses shape the transcriptional network of the human tumor suppressor protein p53. Proceedings of the National Academy of Sciences of the United States of America. 104: 18613-8. PMID 18003932 DOI: 10.1073/Pnas.0703637104  0.508
2007 Papageorgio C, Brachmann R, Zeng J, Culverhouse R, Zhang W, McLeod H. MAGED2: a novel p53-dissociator. International Journal of Oncology. 31: 1205-11. PMID 17912449  0.727
2007 Danziger SA, Zeng J, Wang Y, Brachmann RK, Lathrop RH. Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants. Bioinformatics (Oxford, England). 23: i104-14. PMID 17646286 DOI: 10.1093/bioinformatics/btm166  0.362
2007 Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW, Yi SY, Brachmann RK. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis. 28: 289-98. PMID 16861262 DOI: 10.1093/carcin/bgl132  0.726
2006 Bichutskiy VY, Colman R, Brachmann RK, Lathrop RH. Heterogeneous biomedical database integration using a hybrid strategy: a p53 cancer research database. Cancer Informatics. 2: 277-87. PMID 19458771 DOI: 10.4137/Cin.S0  0.476
2006 Danziger SA, Swamidass SJ, Zeng J, Dearth LR, Lu Q, Chen JH, Cheng J, Hoang VP, Saigo H, Luo R, Baldi P, Brachmann RK, Lathrop RH. Functional census of mutation sequence spaces: the example of p53 cancer rescue mutants. Ieee/Acm Transactions On Computational Biology and Bioinformatics / Ieee, Acm. 3: 114-25. PMID 17048398 DOI: 10.1109/Tcbb.2006.22  0.522
2006 Kobayashi T, Wang T, Maezawa M, Kobayashi M, Ohnishi S, Hatanaka K, Hige S, Shimizu Y, Kato M, Asaka M, Tanaka J, Imamura M, Hasegawa K, Tanaka Y, Brachmann RK. Overexpression of the oncoprotein prothymosin alpha triggers a p53 response that involves p53 acetylation. Cancer Research. 66: 3137-44. PMID 16540664 DOI: 10.1158/0008-5472.CAN-05-2112  0.607
2004 Dearth LR, Brachmann RK. ATP, Cancer and p53. Cancer Biology & Therapy. 3: 638-40. PMID 15326374  0.602
2004 Brachmann RK. p53 mutants: the achilles' heel of human cancers? Cell Cycle (Georgetown, Tex.). 3: 1030-4. PMID 15280671  0.717
2002 Qian H, Wang T, Naumovski L, Lopez CD, Brachmann RK. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene. 21: 7901-11. PMID 12420228 DOI: 10.1038/sj.onc.1205974  0.508
Show low-probability matches.